IL298299A - Treatment of cardiometabolic disease with inhibitors of type i interferon signalling - Google Patents

Treatment of cardiometabolic disease with inhibitors of type i interferon signalling

Info

Publication number
IL298299A
IL298299A IL298299A IL29829922A IL298299A IL 298299 A IL298299 A IL 298299A IL 298299 A IL298299 A IL 298299A IL 29829922 A IL29829922 A IL 29829922A IL 298299 A IL298299 A IL 298299A
Authority
IL
Israel
Prior art keywords
ifn
patient
patients
anifrolumab
dna
Prior art date
Application number
IL298299A
Other languages
English (en)
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL298299A publication Critical patent/IL298299A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL298299A 2020-05-29 2021-05-28 Treatment of cardiometabolic disease with inhibitors of type i interferon signalling IL298299A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063031854P 2020-05-29 2020-05-29
PCT/EP2021/064312 WO2021239928A2 (en) 2020-05-29 2021-05-28 Treatment of cardiometabolic disease

Publications (1)

Publication Number Publication Date
IL298299A true IL298299A (en) 2023-01-01

Family

ID=76269736

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298299A IL298299A (en) 2020-05-29 2021-05-28 Treatment of cardiometabolic disease with inhibitors of type i interferon signalling

Country Status (10)

Country Link
US (1) US12410254B2 (cg-RX-API-DMAC10.html)
EP (2) EP4157873A2 (cg-RX-API-DMAC10.html)
JP (1) JP2023527054A (cg-RX-API-DMAC10.html)
KR (1) KR20230018446A (cg-RX-API-DMAC10.html)
CN (1) CN115667309A (cg-RX-API-DMAC10.html)
AU (1) AU2021279277A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022023438A2 (cg-RX-API-DMAC10.html)
CA (1) CA3183611A1 (cg-RX-API-DMAC10.html)
IL (1) IL298299A (cg-RX-API-DMAC10.html)
WO (1) WO2021239928A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
KR20230110304A (ko) * 2020-11-18 2023-07-21 아스트라제네카 아베 스테로이드 절약
TW202317617A (zh) * 2021-04-23 2023-05-01 瑞典商阿斯特捷利康公司 皮膚紅斑狼瘡之治療
SMT202300382T1 (it) 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087339A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
JP2006512102A (ja) 2002-04-11 2006-04-13 メディミューン・ヴァクシンズ・インコーポレーテッド 噴霧乾燥による生物活性材料の防腐
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
KR20050088175A (ko) 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
NZ545314A (en) * 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
CN107110939B (zh) * 2014-09-11 2021-05-14 力保科学公司 用于测定心血管疾病或事件的风险参数的系统
SI3769781T1 (sl) 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
FI20177098A1 (fi) * 2017-08-29 2019-03-01 Leppaeluoto Juhani Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen
SG11202101946YA (en) * 2018-09-18 2021-04-29 I Mab Biopharma Hangzhou Co Ltd Anti-ifnar1 antibodies for treating autoimmune diseases
EP3881233A4 (en) * 2018-11-15 2022-11-23 Ampel Biosolutions, LLC DISEASE PREDICTION AND TREATMENT PRIORIZATION WITH MACHINE LEARNING

Also Published As

Publication number Publication date
BR112022023438A2 (pt) 2022-12-20
WO2021239928A3 (en) 2022-01-27
KR20230018446A (ko) 2023-02-07
WO2021239928A2 (en) 2021-12-02
CA3183611A1 (en) 2021-12-02
CN115667309A (zh) 2023-01-31
US20240158519A1 (en) 2024-05-16
AU2021279277A1 (en) 2023-02-02
EP4566667A3 (en) 2025-09-03
JP2023527054A (ja) 2023-06-26
WO2021239928A9 (en) 2022-03-17
EP4566667A2 (en) 2025-06-11
EP4157873A2 (en) 2023-04-05
US12410254B2 (en) 2025-09-09

Similar Documents

Publication Publication Date Title
Kopp et al. Podocytopathies
Fijolek et al. Eosinophilic granulomatosis with polyangiitis–advances in pathogenesis, diagnosis, and treatment
Sieb Myasthenia gravis: an update for the clinician
JP2022141868A (ja) 心血管リスクを低減させる方法
Schmidt et al. Pemphigoid diseases
EP4566667A2 (en) Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
van Noort et al. Therapeutic intervention in multiple sclerosis with alpha B-crystallin: A randomized controlled phase IIa trial
Tarzi et al. Current and future prospects in the management of granulomatosis with polyangiitis (Wegener’s granulomatosis)
IL293572A (en) Treatment methods using ilt7 binding proteins
IL301759A (en) Treatment of lupus flares
IL297737A (en) Treatment methods for covid-19
US20230364228A1 (en) Method of treating amyloidosis
TW202133877A (zh) 全身性紅斑狼瘡中之ｉ型干擾素抑制
US20240317876A1 (en) Treatment Of Multiple Sclerosis And Neuromyelitis Optica
Travis et al. The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy
IL300415A (en) Methods for treating multiple sclerosis with ocralizumab
JP2023506732A (ja) ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用
WO2023056305A1 (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
IL278968A (en) Methods for treating atopic dermatitis by administering an IL-4R antagonist
WO2022238479A1 (en) Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
EP4442705A1 (en) Dosage
Kopp et al. Podocytopathies (Primer)
TW202613167A (zh) 使用抗ｔｌ１ａ抗體治療發炎性腸病之方法
JP2025535457A (ja) 原発性膜性腎症を治療するための方法
EA053286B1 (ru) Способ лечения амилоидоза